Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Corless

Showing results (151-160 of 208) with videos related to

Pageof 21
Sort By:
Science (New York, N.Y.)|January 11, 2003
PDGFRA activating mutations in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Anette Duensing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
Large-scale analysis of KIT aberrations in Chinese patients with melanomaYan Kong, Lu Si, Yanyan Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
KIT gene mutations and copy number in melanoma subtypesCarol Beadling, Erick Jacobson-Dunlop, F Stephen Hodi, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|August 23, 2019
A case of recurrent epilepsy-associated rosette-forming glioneuronal tumor with anaplastic transformation in the absence of therapyAaron Halfpenny, Sean P Ferris, Marjorie Grafe, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|March 12, 2014
Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project"Peter H O'Donnell, Keith Danahey, Michael Jacobs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITCharles D Blanke, George D Demetri, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinomaLawrence P Leichman, Bryan H Goldman, Pierre O Bohanes, et al.
JCO Precision Oncology|July 12, 2021
Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast CancerSwapnil Parmar, Jamie M Keck, Ben Kong, et al.
Cold Spring Harbor Molecular Case Studies|August 25, 2021
Mechanisms of targeted therapy resistance in a pediatric glioma driven by <i>ETV6-NTRK3</i> fusionClare Keddy, Tanaya Neff, Jianya Huan, et al.
Transplantation|March 22, 2002
Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplantsSusan L Orloff, Daniel N Streblow, Cecilia Soderberg-Naucler, et al.
Pageof 21

Showing results (151-160 of 208) with videos related to

Sort By:
Pageof 21
Science (New York, N.Y.)|January 11, 2003
PDGFRA activating mutations in gastrointestinal stromal tumorsMichael C Heinrich, Christopher L Corless, Anette Duensing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
Large-scale analysis of KIT aberrations in Chinese patients with melanomaYan Kong, Lu Si, Yanyan Zhu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
KIT gene mutations and copy number in melanoma subtypesCarol Beadling, Erick Jacobson-Dunlop, F Stephen Hodi, et al.
Neuropathology : Official Journal of the Japanese Society of Neuropathology|August 23, 2019
A case of recurrent epilepsy-associated rosette-forming glioneuronal tumor with anaplastic transformation in the absence of therapyAaron Halfpenny, Sean P Ferris, Marjorie Grafe, et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics|March 12, 2014
Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project"Peter H O'Donnell, Keith Danahey, Michael Jacobs, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITCharles D Blanke, George D Demetri, Margaret von Mehren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinomaLawrence P Leichman, Bryan H Goldman, Pierre O Bohanes, et al.
JCO Precision Oncology|July 12, 2021
Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast CancerSwapnil Parmar, Jamie M Keck, Ben Kong, et al.
Cold Spring Harbor Molecular Case Studies|August 25, 2021
Mechanisms of targeted therapy resistance in a pediatric glioma driven by <i>ETV6-NTRK3</i> fusionClare Keddy, Tanaya Neff, Jianya Huan, et al.
Transplantation|March 22, 2002
Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplantsSusan L Orloff, Daniel N Streblow, Cecilia Soderberg-Naucler, et al.
Pageof 21